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Abstract
GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland
morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor
suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was
previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers
of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland
(Ptrend =0.004), with some evidence for a stronger association with estrogen receptor (ER) negative
tumours [1]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast
Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium
of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and
breast cancer risk in BCAC cases overall (ORper-allele = 1.00, 95% CI 0.94 − 1.05), in ER negative
BCAC cases (ORper-allele = 1.02, 95% CI 0.91−1.13), in BRCA1 mutation carriers RRper-allele = 0.99,
95% CI 0.90−1.09) or BRCA2 mutation carriers (RRper-allele = 0.93, 95% CI 0.80−1.07). We conclude
that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium
with it, is associated with breast cancer risk in women.
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Introduction
The GATA-binding protein 3 (GATA3) transcription factor is crucial to mammary gland
morphogenesis and differentiation of progenitor cells, and continues to be expressed in normal
breast luminal epithelial cells throughout puberty and pregnancy [2-4]. Gene expression
profiling aimed at correlating genotypic and phenotypic characteristics of breast tumors has
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implicated GATA3 in tumorigenesis of luminal A subtypes which are associated with more
favourable survival than other subtypes [5-7]. GATA3 expression is strongly correlated with
ER expression [8,9], and its utility in predicting clinical outcome in ER-positive tumors has
also been reported [10,11]. GATA3 somatic mutations have been identified in a subset of ER-
positive breast tumors, and cells transfected with these GATA3 mutants show increased
proliferation compared with wild-type transfectants, suggesting a tumor suppressor function
[12]. Analysis of association between breast cancer and GATA3 single nucleotide
polymorphisms (SNPs) in two European studies suggested that rs570613, in intron 4, was
associated with a 15−18% overall reduction in breast cancer risk (Ptrend =0.004), with some
evidence for a stronger association with ER-negative tumors [1]. To test this association, we
analysed this SNP in case-control studies and BRCA1 and BRCA2 carriers from two large
consortia.
Materials and Methods
Analysis of breast cancer risk was based on genotype data from 6,388 cases (largely population-
based) and 4,995 controls identified through five European and Australian studies (ABCFS,
GENICA, HEBCS, SASBAC and kConFab; Table 1) in the Breast Cancer Association
Consortium (BCAC; ref. 13), and 5,617 BRCA1 and BRCA2 mutation carriers from 11 studies
from Europe, Australia and North America (EMBRACE, DNA-HEBON, kConFab, SWE-
BRCA, MUV, UPENN, MAYO, HEBCS, FCCC, PBCS and Georgetown; ref. 14,15) in the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). The design, for both
consortia, genotyping methods and quality control procedures have been reported elsewhere
[14,15]. All statistical tests were two sided, and analyses were carried out using the S-Plus
(Insightful Corp.) software system and STATA v. 9.0 (Stata Corp.). Statistical significance
was based on a nominal P-value less than 0.05.
For the BCAC study, odds ratios (ORs) for heterozygotes and homozygotes, relative to the
common homozygotes, were estimated using logistic regression, adjusted for age and study,
together with per allele ORs (estimated by fitting the number of rare alleles carried as a
continuous covariate). Similar methods were used to obtain risk estimates according to ER
status where data were available.
For the CIMBA study, the associations between breast cancer risk and GATA3 rs570613
genotypes for BRCA1 and BRCA2 mutation carriers were estimated using Cox proportional
hazards regression analysis with breast cancer as the outcome and age as the time-to-event
variable [16]. Subjects were followed from birth until breast cancer, bilateral prophylactic
mastectomy, ovarian cancer, age at last contact, or age 80. A weighted cohort approach was
used to adjust estimates for the potential over-sampling of affected individuals [17]. Rate ratios
(RR) and 95% CIs were estimated for all carriers combined, and for BRCA1 and BRCA2
mutation carriers separately, for heterozygotes and rare homozygotes compared with common
homozygotes, and per allele. To allow for the fact that the CIMBA cohort includes related
individuals we used a robust variance approach to compute the variance of the RRs [18].
Additional analyses were conducted by adjusting for oophorectomy status as a time dependent
covariate and by excluding affected individuals who were recruited more than five years after
breast cancer diagnosis.
Results
All contributing studies met genotyping quality control criteria [14,15]. In BCAC controls the
combined mean age at interview was 53.1 (SD 14.2) and in cases the age at diagnosis was 54.6
(SD 12.5). Table 1 shows genotype frequencies for cases and controls for each BCAC study,
together with study-specific and pooled ORs and 95% CIs for association between the
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GATA3 rs570613 SNP and breast cancer, both overall and stratified on ER status. GATA3
genotypes were not associated with breast cancer risk for either the combined analysis, or for
any of the five individual studies. Similar analyses stratified by ER status also showed no
association between GATA3 genotypes and risk of either ER-positive or ER-negative tumors.
In the CIMBA study, there was no evidence of an association between risk of breast cancer
and rs570613 genotypes, in BRCA1 and BRCA2 carriers pooled, or when BRCA1 and
BRCA2 carriers were analysed separately (Table 2). Analyses adjusting for oophorectomy
status, or restricted to cases ascertained within five years of diagnosis, likewise showed no
association (Table 2).
Discussion
Our study comprehensively evaluated the GATA3 rs570613 SNP for association with risk of
breast cancer, but failed to replicate the previous report of an association with risk. The BCAC
analysis had ∼99% power to detect an OR of the magnitudes previously reported (0.82−0.85),
and the 95% CI for the per-allele OR (0.94−1.05) shows that we can exclude all but very small
associations. Likewise, GATA3 rs570613 genotypes were not associated with breast cancer
risk in BRCA1 and BRCA2 mutation carriers. Results remained similar when analyses were
adjusted for oophorectomy status in a time-dependent manner or when cases diagnosed more
than five years before recruitment were excluded to account for possible survival bias. There
was no evidence of an association with ER status in BCAC studies but the number of ER-
negative cases was limited to 868, and hence the 95% CI was wider (0.91−1.13). However,
most BRCA1-associated tumors are ER-negative [19], so the absence of any association in
BRCA1 carriers is consistent with the lack of an association with ER-negative disease. The
potential for variation in study-specific estimates is inherent in consortium analyses involving
multiple studies. However, all BCAC studies selected controls from the same source population
as cases, participants being predominantly Caucasian. There was no evidence of heterogeneity
in risk estimates from either consortiium analysis (PHeterogeneity ≥0.3). In summary, the role of
GATA3 in breast tumor biology and prognosis has been well documented [20] and the
hypothesis that variants in GATA3 might influence breast cancer risk is appealing. However,
our data demonstrate convincingly that neither rs570613, nor any SNP in significant linkage
disequilibrium with it, is likely to have a major influence on breast cancer risk.
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